TX-FLUENCE
Fluence , a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today its exclusive partnership with BioLumic , a plant-growth biotechnology company that harnesses the power of ultraviolet (UV) light to sustainably increase plant yields, health and quality with Light Signal Recipes™. Under the agreement, Fluence and BioLumic will collaborate to deliver BioLumic’s cutting-edge UV Light Signals through Fluence’s industry-leading LED lighting solutions.
BioLumic’s patented technology leverages UV photomorphogenesis to trigger biological events in seeds and young plants to dramatically optimize plant performance. The company’s proven UV Light Signal Recipes™ can induce large gains in plant yields, desirable plant traits and vigor while also activating natural plant resistance to disease and pests.
“Our goal at Fluence is to drive cutting-edge plant science and innovations in agriculture technology,” said David Cohen, CEO of Fluence. “We’re excited to pursue that goal in collaboration with BioLumic and create the next generation of leading lighting solutions for cannabis and produce growers around the world.”
Fluence’s lighting systems will deliver BioLumic’s dynamic UV light treatments in the propagation phase of plant production—one-time treatments that trigger benefits that accrue through the entire plant growth cycle. Pairing BioLumic and Fluence’s leading market solutions enables cultivators to achieve high-quality yield gains, enhance cannabinoid levels and improve overall plant quality while reducing cycle-to-cycle variability.
“BioLumic’s Light Signal Recipes™ allow cultivators to fully and frictionlessly harness UV lighting to improve plant growth and genetic expression without big input costs or chemicals,” said Steve Sibulkin, CEO of BioLumic. “This partnership will accelerate the development of BioLumic’s Light Signal Platform, increase our company’s access to the global horticulture market and strengthen Fluence’s horticultural lighting portfolio. It’s a tremendous win for growers looking for new ways to grow more with less.”
The partnership reinforces Fluence’s deep history of science-led innovation in photobiology and follows several product launches this year, including RAPTR, RAZR Modular System, VYNE, SPYDR Fang, SPYDR 2h and Wireless Flex Dimming. Fluence’s dynamic and expanding suite of luminaires and lighting controls empowers growers with advanced lighting technology that meets and exceeds cultivation goals.
Fluence and BioLumic will initially work with select cannabis cultivation partners while industrializing commercial delivery systems for UV light that enhance Fluence’s end-to-end product offering in 2023. For more information about BioLumic, please visit www.biolumic.com . For more information about Fluence, visit www.fluence.science .
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science .
About BioLumic
BioLumic is an agricultural biotech company that programs plants with light to unlock growth, quality and disease-resistance. The company's Light Signal Recipe™ platform combines biological insights and genetic marker knowledge to mediate genetic expression with a one-time application of light signals. These treatments are scalable and require no chemical application, genetic modification, facility expansion or large input costs. BioLumic has worked with 12 crops, including cannabis, soybeans, corn, leafy greens and strawberries. In cannabis, the company has helped cultivators produce large double-digit gains in dry flower yield, THC concentration, minor cannabinoids and terpene expression. To learn more, visit www.biolumic.com or send an email to info@biolumic.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220714005019/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lone Star Announces Sale of SPX FLOW to ITT Inc.5.12.2025 13:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced the signing by an affiliate of Lone Star Fund XI, LP of a definitive agreement to sell SPX FLOW, Inc. (“SPX FLOW”), a leading provider of highly engineered equipment and process technologies for attractive end markets including industrial, health and nutrition, to ITT Inc. (NYSE: ITT) for $4.775 billion in cash and shares of common stock. Based in Charlotte, N.C., SPX FLOW focuses on process technologies delivering mixing, blending, fluid handling, separation, thermal heat transfer and other solutions integral to industrial, health and nutrition markets. The company has operations in more than 25 countries and sales in more than 140 countries. In partnership with Lone Star, SPX FLOW has focused on improving its sales execution and operating platform, while ensuring high quality and innovative product development. The management team has improved the company’s commercial organization and executed growth initiatives to build its presence in e
AmTrust Financial Services and Blackstone Credit & Insurance Close Strategic Transaction and Launch Newly Formed Multinational MGACompany Named ANV Group Holdings Ltd.5.12.2025 13:00:00 CET | Press release
Strategic Transaction Unlocks Value for AmTrust and Positions ANV Group Holdings for Accelerated GrowthFormer AmTrust President Adam Karkowsky Leading ANV Group Holdings as Chairman and CEO AmTrust Financial Services, Inc. (“AmTrust” or the “Company”), a global specialty property casualty insurer, and Blackstone Credit & Insurance (“BXCI”), today announced the closing of a strategic transaction under which AmTrust and funds managed by BXCI have partnered to spin-off certain of AmTrust’s Managing General Agencies (“MGAs”) and fee-based businesses in the U.S., United Kingdom, and Continental Europe, into ANV Group Holdings Ltd. (“ANV”), a newly formed independent company, following receipt of regulatory approvals. AmTrust and ANV have entered into a ten-year capacity agreement through which AmTrust will remain the underwriter for the existing books of business offered through the MGAs. As previously announced on September 15, 2025, the agreement includes seven AmTrust subsidiaries: ANV S
Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body5.12.2025 07:00:00 CET | Press release
Sculptra®, the first proven regenerative biostimulator, has received European Union (EU) Medical Device Regulation (MDR) certification, expanding its current clinical application for the face to include gluteal area, posterior thighs, décolletage, and upper arms1 Studies investigating the efficacy of Sculptra on areas beyond the face show patients experienced progressive improvements in skin quality (including the improvement in cellulite appearance), firmness, lift, projection, and contour Sculptra’s versatility and new indication allow practitioners to shift patient treatment goals beyond rejuvenation toward enhancement, meeting evolving patient needs The certification validates Sculptra’s safety performance, efficacy, and quality, reinforcing Galderma’s commitment to innovation and meeting evolving patient needs Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its
Northern Escape Heli-Skiing Takes the Title of “World’s Best Heli-Ski-Operator” for the 4th Year Running5.12.2025 02:40:00 CET | Press release
4x World’s Best Heli-Skiing Operation near Terrace, BC Northern Escape Heli-Skiing (NEH) has been named World’s Best Heli-Ski Operator 2025 by the World Ski Awards, marking its fourth straight victory following years 2022, 2023 and 2024. This recognition places NEH amongst an elite group of ski tourism operators consistently voted best in the world by industry leaders and enthusiasts alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204074550/en/ A four-year run built on reliability NEH operates in British Columbia’s Skeena Mountains, where deep northern snow and vast terrain come together with small-group heli-skiing and heli snowboarding. When helicopters can’t safely fly, NEH has cat skiing readily available as a backup — an exceedingly rare offering in this industry. The operation spans over 833,571 wild acres of alpine bowls, glaciers and old-growth tree skiing. The NEH experience Guests choose from three lodge f
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance5.12.2025 01:00:00 CET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC). IDEAYA expects to begin patient enrollment in Q1 2026, initially evaluating patients with solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck, and ovarian/gynecological cancers. IDE034 is a bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and licensed to IDEAYA in July 2024. The IND clearance marks an important milestone for this licensed program, supporting subsequent clinical development of IDE034, while highlighting Biocytogen’s technical capabilities in bispecific ADC discovery and development. Dr. Yue
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom